Adamis Pharma (ADMP) Gets a Buy Rating from Maxim Group

By Ryan Adsit

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP) today and set a price target of $13. The company’s shares opened today at $3.

McCarthy noted:

“The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced).”

According to, McCarthy is a 5-star analyst with an average return of 15.6% and a 47.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adamis Pharma with a $9 average price target, a 200.0% upside from current levels. In a report issued on September 10, H.C. Wainwright also maintained a Buy rating on the stock with a $7 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $5.85 and a one-year low of $2.20. Currently, Adamis Pharma has an average volume of 962K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamis Pharmaceuticals Corp. is a biopharmaceutical company which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.. Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians.